An audit into granulocyte-colony stimulating factor (G-CSF) primary prophylaxis for early breast cancer chemotherapy at the North Middlesex University Hospital (NMUH)

2016 ◽  
Vol 28 ◽  
pp. S12-S13
Author(s):  
T.C. Smith ◽  
S. Jenkinson ◽  
F. Raja
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Cancer Chemotherapy ◽  
Primary Prophylaxis ◽  
University Hospital ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Breast Cancer Chemotherapy ◽  
The North ◽  
Stimulating Factor

scholarly journals Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin

Medicina ◽  
2009 ◽  
Vol 45 (8) ◽  
pp. 600 ◽  
Author(s):  
Sigita Liutkauskienė ◽  
Audrius Sveikata ◽  
Elona Juozaitytė ◽  
Dainius Characiejus ◽  
Edita Juodžbalienė ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Febrile Neutropenia ◽  
Adverse Events ◽  
Metastatic Breast ◽  
Primary Prophylaxis ◽  
Life Assessment ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

Background. We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer. Patients and methods. Three centers in Lithuania enrolled 36 patients who received rGCSF (5 μg/kg/d) on day 2 of each 21-day chemotherapy with docetaxel 75 mg/m2 and doxorubicin 50 mg/m2 (AT) starting in the first cycle. Treatment regimen was repeated for up to six cycles. Results. Leukocytosis, bone pain, and headache were the most frequent adverse events, with incidence rates of 22%, 19%, and 8%, respectively. Adverse events were typical for rGCSF in this patient population. Overall incidence rate of febrile neutropenia was 14%. The mean duration of febrile neutropenia episodes across cycles was 2.14 days. Incidence of chemotherapy delay was 2%. There was no reduction in chemotherapy dose due to expected toxicity or side effects. Intravenous antibiotics for the treatment of febrile neutropenia were needed in 19% of cases. Quality-of-life assessment shows a significant improvement in emotional functioning and a significant decrease in pain score. The efficacy profile of rGCSF observed in the present study was comparable with that of other rGCSF products previously described in the published scientific literature. Conclusions. The primary prophylaxis of neutropenia and its complications by rGCSF was safe and effective for women with metastatic breast cancer who received chemotherapy with docetaxel and doxorubicin.

Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?

2006 ◽  
Vol 24 (19) ◽  
pp. 3048-3055 ◽  
Author(s):  
Paola Papaldo ◽  
Gianluigi Ferretti ◽  
Serena Di Cosimo ◽  
Diana Giannarelli ◽  
Paolo Marolla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
High Dose ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
The Mean ◽  
Stimulating Factor

Purpose We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment. Methods Five hundred and six stage I or stage II female breast cancer patients were treated with E 120 mg/m2 and C 600 mg/m2 with or without G-CSF and randomly assigned to receive in a factorial 2 × 2 design: EC; EC + lonidamine; EC + G-CSF; EC + lonidamine + G-CSF. Five consecutive G-CSF schedules tested 100 randomly assigned patients each: (1) 480 μg subcutaneously on days 8 to 14; (2) 480 μg on days 8, 10, 12, 14; (3) 300 μg on days 8 to 14; (4) 300 μg on days 8, 10, 12, and 14; and (5) 300 μg on days 8 and 12. The mean Hb level of 246 patients receiving EC plus G-CSF was compared with that of 240 patients receiving EC alone. The data presented are derived from an exploratory hypothesis-generating analysis. Results The EC dose intensity did not statistically differ between the G-CSF and the control arm. From the third cycle onward, the mean Hb value resulted significantly lower in G-CSF arm compared with control at each time point of each cycle (P < .0001). No statistically significant difference in the mean Hb level was observed between schedule 5 and control. Of interest, from the second course onward, the mean Hb level tended to be lower in patients receiving seven or four G-CSF injections compared with those patients who received only two injections. Conclusion Our data suggest that a G-CSF dose-related effect may play a role in worsening anemia in patients receiving adjuvant EC.

Sign in / Sign up

Export Citation Format

Share Document